In a filing, Werewolf Therapeutics Inc revealed its Director RA CAPITAL MANAGEMENT, L.P. acquired Company’s shares for reported $0.28 million on May 12 ’25. In the deal valued at $0.86 per share,320,913 shares were bought. As a result of this transaction, RA CAPITAL MANAGEMENT, L.P. now holds 6,021,969 shares worth roughly $7.29 million.
Then, RA CAPITAL MANAGEMENT, L.P. bought 162,539 shares, generating $159,288 in total proceeds. Upon buying the shares at $0.98, the Director now owns 6,237,482 shares.
Before that, RA CAPITAL MANAGEMENT, L.P. bought 52,974 shares. Werewolf Therapeutics Inc shares valued at $51,915 were divested by the Director at a price of $0.98 per share. As a result of the transaction, RA CAPITAL MANAGEMENT, L.P. now holds 6,074,943 shares, worth roughly $7.35 million.
JMP Securities initiated its Werewolf Therapeutics Inc [HOWL] rating to a Mkt outperform in a research note published on April 03, 2024; the price target was $12. A number of analysts have revised their coverage, including Wedbush’s analysts, who began to cover the stock in late August with a ‘”an Outperform”‘ rating. BofA Securities started covering the stock on September 10, 2021. It rated HOWL as “a Buy”.
Price Performance Review of HOWL
On Tuesday, Werewolf Therapeutics Inc [NASDAQ:HOWL] saw its stock fall -6.92% to $1.21. Over the last five days, the stock has lost -9.02%. Werewolf Therapeutics Inc shares have fallen nearly -18.24% since the year began. Nevertheless, the stocks have fallen -62.77% over the past one year. While a 52-week high of $4.18 was reached on 01/03/25, a 52-week low of $0.60 was recorded on 04/07/25.
Levels Of Support And Resistance For HOWL Stock
The 24-hour chart illustrates a support level at 1.1600, which if violated will result in even more drops to 1.1100. On the upside, there is a resistance level at 1.3000. A further resistance level may holdings at 1.3900.
The most recent change occurred on May 25, 2021 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $29 price target.
